TREATMENT OUTCOMES OF MULTIDRUG RESISTANT TUBERCULOSIS PATIENTS IN EAST JAVA FROM 2014 TO 2017
Downloads
Background: Multidrug resistant tuberculosis (MDR TB) is a major public health problem marked by the Mycobacterium tuberculosis strain that is resistant to first line anti TB drugs, including rifampicin and isoniazid simultaneously. A patient confirmed as having MDR TB can transmit this form of TB to other individuals. Therefore, treatment success is the main target when addressing MDR TB. Purpose: This study aimed to assess the treatment outcomes of MDR TB patients in East Java Province from 2014 to 2017. Method: This is a quantitative-descriptive study using the secondary data of drug resistant TB patients sourced from the e-TB Manager website in the East Java Province Health Office. Results: The results show that the average MDR TB patients was 47 years old, 57.44% were male, 37.52% had a negative HIV status, 44.87% were relapse patients, 71.95% had undergone two or less previous treatments, and 69.24% had sputum culture conversion. The treatment outcomes included 161 patients (31.14%) confirmed as cured, 27 patients (5.22%) completing treatment, 174 patients (33.65%) defaulting, two patients (0.38%) confirmed as having failed treatment, and 59 patients (11.41%) dying during the treatment period. Conclusion: The treatment success rate was low and the number of defaults was high. Therefore, it is hoped that there will be support from those closest to the patient and health workers who will maintain and increase the patient's motivation to complete the treatment.
Akshata, J. S., & Chakrabarthy, A. (2016). Management of multidrug resistant tuberculosis (MDR-TB) – monitoring is the key to successful outcome. Egyptian Journal of Chest Diseases and Tuberculosis, 65(2), 447–450. https://doi.org/10.1016/j.ejcdt.2015.12.018
Alene, K. A., Viney, K., McBryde, E. S., Tsegaye, A. T., & Clements, A. C. A. (2017). Treatment outcomes in patients with multidrug-resistant tuberculosis in North-West Ethiopia. Tropical Medicine and International Health, 22(3), 351–362. https://doi.org/10.1111/tmi.12826
Alene, K. A., Viney, K., Yi, H., McBryde, E. S., Yang, K., Bai, L., ... Clements, A. C. A. (2018). Comparison of the validity of smear and culture conversion as a prognostic marker of treatment outcome in patients with multidrug-resistant tuberculosis. PLoS ONE, 13(5), 1–17. https://doi.org/10.1371/journal.pone.0197880
Deshmukh, R. D., Dhande, D. J., Sachdeva, K. S., Sreenivas, A., Kumar, A. M. ., Satyanarayana, S., ... Lo, T. Q. (2015). Patient and provider reported reasons for lost to follow up in MDRTB treatment: a qualitative study from a drug resistant TB Centre in India. PLoS ONE, 10(8), 1–11. https://doi.org/10.1371/journal.pone.0135802
Farihatun, S., & Machmud, P. B. (2018). Determinant factors of drop out (Do) among multi drugs resistance tuberculosis (MDR TB) patients at Jakarta Province in 2011 to 2015. Indonesian Journal of Tropical and Infectious Disease, 7(3), 87–92. https://doi.org/10.20473/ijtid.v7i3.7793
Gandhi, N. R., Brust, J. C. M., & Shah, N. S. (2017). A new era for treatment of drug-resistant tuberculosis. European Respiratory Journal, 176(3), 139–148. https://doi.org/10.1016/j.physbeh.2017.03.040
Ghithrif, M. R. (2016). Analisis faktor yang mempengaruhi drop out dalam pengobatan TB MDR di Kabupaten Gresik. Thesis. Faculty of Public Health. Universitas Airlangga.
Gualano, G., Urso, R., Silvia, R., Roberto, T., Daniele, B., Giuseppe, M., ... Fabrizio, P. (2016). Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy. European Respiratory Journal, 48(suppl 60), PA2688. https://doi.org/10.1183/13993003.congress-2016.PA2688
Günther, G., Lange, C., Alexandru, S., Altet, N., Avsar, K., Bang, D., ... van Leth, F. (2016). Treatment outcomes in multidrug-resistant tuberculosis. New England Journal of Medicine, 375(11), 1103–1105. https://doi.org/10.1056/NEJMc1603274
Kobayashi, N., Hattori, T., Akter, S., Mizoue, T., & Ohta, K. (2017). Treatment outcomes in patients with multidrug-resistant tuberculosis in Japan, 2011-2013. European Respiratory Journal, 50(suppl 61), PA3494. https://doi.org/10.1183/1393003.congress-2017.PA3494
Kumar, S., Sharma, K., Agarwal, K. C., & Purohit, S. (2016). Programmatic management of drug resistance tuberculosis: outcome analysis of 200 patients in western part of Rajasthan, India. European Respiratory Journal, 48(suppl 60), PA2673. https://doi.org/10.1183/13993003.congress-2016.PA2673
Kurbatova, E. V., Cegielski, J. P., Lienhardt, C., Akksilp, R., Bayona, J., Becerra, M. C., ... Zignol, M. (2015). Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. The Lancet Respiratory Medicine, 3(3), 201–209. https://doi.org/10.1016/S2213-2600(15)00036-3
Lu, P., Liu, Q., Martinez, L., Yang, H., Lu, W., Ding, X., & Zhu, L. (2017). Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China. European Respiratory Journal, 49(3), 1–4. https://doi.org/10.1183/13993003.01558-2016
Mardhiyyah, A., & Carolia, N. (2016). Multi drug resistant tuberculosis pada pasien drop out dan tatalaksana OAT lini kedua. Majority, 5(2), 11–16.
Ministry of Health RI. (2013). Regulation of the Minister of Health of the Republic of Indonesia number 13 of 2013 concerning integrated management guidelines for controlling drug-resistant tuberculosis. Jakarta: Ministry of Health RI.
Ministry of Health RI. (2016). Minister of Health Regulation number 67 of 2016 concerning tuberculosis prevention. Jakarta: Ministry of Health RI.
Ministry of Health RI. (2017). Integrated management of drug resistant TB control (MTPTRO). Retrieved July, 6, 2020 from https://www.tbindonesia.or.id/page/view/22/tb-mdr
Reviono, Kusnanto, P., Eko, V., Pakiding, H., & Nurwidiasih, D. (2014). Multidrug resistant tuberculosis (MDR-TB): tinjauan epidemiologi dan faktor risiko efek samping obat anti tuberkulosis. Majalah Kedokteran Bandung, 46(4), 189–196.
Seniantara, I. K., Ivana, T., & Adang, Y. G. (2018). Pengaruh efek samping OAT (obat anti tuberculosis) terhadap kepatuhan minum obat pada pasien TBC di puskesmas. Jurnal Keperawatan STIKES Suaka Insan, 3(2), 1–12.
Shibabaw, A., Gelaw, B., Wang, S. H., & Tessema, B. (2018). Time to sputum smear and culture conversions in multidrug resistant tuberculosis at university of gondar hospital, Northwest Ethiopia. PLoS ONE, 13(6), 1–15. https://doi.org/10.1371/journal.pone.0198080
Soepandi, P. (2014). Hasil pengobatan dan variasi biaya TB - MDR / XDR dengan strategi PMDT di RSUP Persahabatan. Jurnal Administrasi Kebijakan Kesehatan, 1(1), 19–25.
Sun, F., Li, Y., Chen, Y., Guan, W., Jiang, X., Wang, X., ... Zhang, W. (2019). Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study. European Respiratory Journal, 53(3), 1801770.
WHO. (2017). Multidrug-resistance tuberculosis (MDR-TB): 2017 Update. Wold Health Organization. USA. Retrieved October, 3, 2019, from http://apps.who.int/iris/bitstream/10665/130918/1/9
Widyasrini, E. R., Probandari, A. N., & Reviono. (2017). Factors affecting the success of multi drug resistance (MDR-TB) tuberculosis treatment in residential Surakarta. Journal of Epidemiology and Public Health, 2(1), 45–57.
Yasin, R., Abu Bakar, Z., & Abdul Muttalif, A. R. (2014). Analysis of multidrug-resistant tuberculosis. European Respiratory Journal, 44(Suppl 58), P2646.
- Every manuscript submitted to must observe the policy and terms set by the Jurnal Berkala Epidemiologi
- Publication rights to manuscript content published by the Jurnal Berkala Epidemiologi is owned by the journal with the consent and approval of the author(s) concerned. (download copyright agreement)
- Complete texts of electronically published manuscripts can be accessed free of charge if used for educational and research purposes according to copyright regulations.
JBE by Universitas Airlangga is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
